BHVN EBITDA | Biohaven Ltd.

Biohaven Ltd. EBITDA

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of the cash a company's operations generate before accounting charges for wearing out its assets. Here it is operating income plus the filed depreciation and amortization, not a figure the company adjusted itself. Higher EBITDA means more operating profit before those charges. It is not an official accounting (GAAP) measure and does not subtract capital spending, interest or tax, so it does not show what those obligations cost.

Biohaven Ltd. ebitda for the quarter ending 2026-06-30 was -$122.64M, a change of $87.08M year-over-year.
Biohaven Ltd. ebitda for the quarter ending 2026-03-31 was -$128.06M, a change of $91.25M year-over-year.
Biohaven Ltd. ebitda for the quarter ending 2025-12-31 was -$140.16M, a change of $47.31M year-over-year.
Biohaven Ltd. ebitda for the quarter ending 2025-09-30 was -$166.26M, a change of $9.92M year-over-year.
Biohaven Ltd. ebitda for fiscal 2025 was -$735.46M, a change of $141.8M from fiscal 2024.
Biohaven Ltd. ebitda for fiscal 2024 was -$877.26M, a change of -$448.12M from fiscal 2023.
Biohaven Ltd. ebitda for fiscal 2023 was -$429.14M, a change of $137.41M from fiscal 2022.
Biohaven Ltd. ebitda for fiscal 2022 was -$566.55M, a change of -$349.04M from fiscal 2021.

Available history: 2020-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$122.64M	-$124.9M	$2.26M	(m)	(m)	$454.00K*	-$85.10M*	(m)	$100.81M	(m)	$391.00K
2026-03-31	Reported	-$128.06M	-$130.43M	$2.37M	(m)	(m)	$0.00	-$149.92M	(m)	$103.83M	(m)	$272.00K
2025-12-31	Reported	-$140.16M	-$142.73M	$2.57M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$166.26M	-$169.38M	$3.13M	(m)	(m)	$13.00K*	-$145.72M*	(m)	$141.17M	(m)	$221.00K
2025-06-30	Reported	-$209.72M	-$211.7M	$1.98M	(m)	(m)	$233.00K*	-$167.94M*	(m)	$184.37M	(m)	$261.00K
2025-03-31	Reported	-$219.32M	-$221.56M	$2.25M	(m)	(m)	$461.00K	-$165.12M	(m)	$187.58M	(m)	$609.00K
2024-12-31	Reported	-$187.47M	-$189.93M	$2.46M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$176.17M	-$178.17M	$1.99M	(m)	(m)	$611.00K*	-$141.28M*	(m)	$157.61M	(m)	-$59.00K
2024-06-30	Reported	-$331.82M	-$333.77M	$1.95M	(m)	(m)	$2.95M*	-$167.80M*	(m)	$314.82M	(m)	$177.00K
2024-03-31	Reported	-$181.79M	-$183.24M	$1.45M	(m)	(m)	$440.00K	-$102.64M	(m)	$155.97M	(m)	$569.00K
2023-12-31	Reported	-$151.82M	-$153.71M	$1.89M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$109.01M	-$110.55M	$1.54M	(m)	(m)	$1.25M*	-$94.81M*	(m)	$95.52M	(m)	-$3.29M
2023-06-30	Reported	-$92.18M	-$94.01M	$1.83M	(m)	(m)	$595.00K*	-$44.39M*	(m)	$79.49M	(m)	$2.18M
2023-03-31	Reported	-$76.13M	-$77.78M	$1.65M	(m)	(m)	$735.00K	-$77.64M	(m)	$63.46M	(m)	$939.00K
2022-12-31	Reported	-$213.07M	-$213.41M	$344,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$67.26M	-$67.64M	$377,000.00	(m)	(m)	$4.52M*	-$95.56M*	(m)	$52.84M	(m)	$1.22M
2022-06-30	Reported	-$196.7M	-$197.11M	$415,000.00	(m)	(m)	$1.00M*	-$67.89M*	(m)	$177.09M	(m)	$6.11M
2022-03-31	Reported	-$89.52M	-$89.77M	$250,000.00	(m)	(m)	$246.00K	-$58.84M	(m)	$70.10M	(m)	$7.25M
2021-12-31	Reported	-$50.2M	-$50.88M	$685,000.00	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$55.32M	-$55.49M	$172,000.00	(m)	(m)	(m)	(m)	(m)	$46.97M	(m)	-$1.13M

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$735.46M	-$745.38M	$9.92M	(m)	(m)	$715.00K	-$609.44M	(m)	$635.07M	(m)	$1.44M
2024-12-31	Reported	-$877.26M	-$885.11M	$7.86M	(m)	(m)	$4.05M	-$582.45M	(m)	$795.87M	(m)	$735.00K
2023-12-31	Reported	-$429.14M	-$436.05M	$6.91M	(m)	(m)	$3.05M	-$331.73M	(m)	$373.28M	(m)	-$1.38M
2022-12-31	Reported	-$566.55M	-$567.93M	$1.39M	(m)	(m)	$6.07M	-$297.69M	(m)	$437.07M	(m)	$438.00K
2021-12-31	Reported	-$217.51M	-$218.9M	$1.39M	(m)	(m)	$938.00K	-$145.84M	(m)	$181.49M	(m)	$1.37M
2020-12-31	Reported	-$114.43M	-$114.51M	$72,000.00	(m)	(m)	$1.10M	-$75.96M	(m)	$98.46M	(m)	$0.00

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Nuvation Bio Inc. (NUVB)	United States	$2.007B	-13.12
UroGen Pharma Ltd. (URGN)		$2.015B	-18.42
AGIOS PHARMACEUTICALS, INC. (AGIO)	United States	$1.962B	-5.38
NEKTAR THERAPEUTICS (NKTR)	United States	$2.026B	-9.05
PERRIGO Co plc (PRGO)	Ireland	$2.038B	-0.79
Sarepta Therapeutics, Inc. (SRPT)	United States	$1.941B	-13.89
Generate Biomedicines, Inc. (GENB)	United States	$2.052B
Zymeworks Inc. (ZYME)	United States	$1.902B	-12.44
Trevi Therapeutics, Inc. (TRVI)	United States	$2.091B	-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)	United States	$2.105B	-35.55